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Summary: A rapid simple test for measuring normalised serum thyroxine is described in detail, using small Sephadex
columns. A small portion of test serum is reintroduced into the test system at the competitive binding stage, so that
corrected T4 values are obtained when the concentrations of thyroxine binding globulin are variable. Only 125
serum is required for the whole test.
Values obtained by the present method correlated well with the product of thyroxine concentration and radioactive
T3 uptake (T4-RT3U index) and with a commercially available method for normalized thyroxine (T4N). Day-to-day
variation was CV = 6%.
Verfahren fur die Bestimmung des normalisierten Thyroxins in kleinen Sephadex-Säulen
Zusammenfassung: Ein schneller, einfacher Test für die Messung des normalisierten Thyroxins im Serum mit kleinen
Sephadex-Säulen wird im Detail beschrieben. In Fällen abweichender Konzentrationen an Thyroxin-bindendem
Globulin werden korrigierte Thyroxinwerte erhalten, wenn eine kleine Portion von Patientenserum während der
kompetitiven Bindung nochmals in das Testsystem gegeben wird. Für den gesamten Test werden nur 125 Serum
benötigt.
Die mit der vorgestellten Methode erhaltenen Werte korrelieren gut mit dem Produkt aus Thyroxin-Gesamtkonzen-
tration und Aufnahme von radioaktivem Trijodthyronin (T4-RT3U-Index) und den Werten eines kommerziell erhält-
lichen Verfahrens für normalisiertes Thyroxih (T4N). Der Variationskoeffizient von Tag zu Tag beträgt 6%.
Introduction T3 uptake (RT^U) may lead to an incorrect diagnosis of
, , ^ hyper- or hypothyroidism. However, determination of
It is generally agreed that the concentration of free ^
 ftee th oxine fraction (Le. the prOpOrtiOn of total
thyroxine io serum is the most useful clinical test in thyroxine present in the free form) is tedious and too
assessing thyroid function, since the free hormone complex for routine clinical use. An indirect measurement
available to the peripheral tissues is responsible for the
 of ffee thyroxine in the serum is given by the product of
hormonal action (1). The quantity of thyroxine binding
 thyroxine concentration and T3 uptake, the T4-RT3U
globulin to which thyroxine is almost entirely bound, is
 iRd?x whjch tenda to refject the thyroid status unaltered
altered in many clinical states. An increase is related to
 by ch ^ Q{ thyroxine binding globu]in concentration,
excess estrogens in pregnancy or in women receiving
oral contraceptives and a decrease may arise from andre*
 Another approach is the assessment of thyroid function
genie anabolic steroids (2).
 using ? normaiised thyroxine assay: T4N (3). This pro-
Due to alterations in thyroxine binding blobulin concen- cedure involves a modification of the determination of
tration, total thyroxine estimation (T4D) and radioactive total thyroxine. To the initial serum sample is added
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another smaller sample of the same serum, together with
the binding globulin present in the second serum sample
to contribute in the competitive protein binding of
thyroxine. By adding the second portion of serum
sample, the revised thyroxine determination becomes
more a reflection of the minute amount of free thyroxine
present. This is more closely related to the actual thyroid
status of the patient than the total thyroxine concen-
tration.
The purpose of the normalised thyroxine or T4N determ-
ination is to provide the same information as the
combination of total thyroxine and T3*) uptake (RT3U
ratio) (4).
This communication presents a modification of the T4N
procedure in small Sephadex columns. The main advant-
age of our method in comparison to a previous method
is that only 0.125 ml serum is required for test instead
of 0.32 ml in the method ofAbreau et al (1), thus the
present test is easily applied to very young children.
The principles of the test can be described as follows:
- thyroxine is separated from the serum by pipetting
onto a strong alkaline Sephadex column
- the liberated thyroxine, along with the added [125I]-
thyroxine tracer in the alkaline medium, is bound by
the Sephadex
- the column is washed with 75 mmol/1 barbital buffer
to shift the pH of the column to 8.6 and to wash out
any free 125I and the serum proteins (and possible
interfering substances such as non-esterified fatty
acids) which are now virtually free of thyroxine
— as eluting reagent thyroxine binding globulin solution
together with a second aliquot of 25 μΐ the patient's
serum is added
— equilibrium is established between the Sephadex
column and the proteins of the eluting reagent
- the thyroxine bound to the eluting reagent is removed
from the Sephadex column by washing with buffer at
pH8.6
- the percentage radioactivity retained by the column
is determined
The nature of thyroxine binding to Sephadex is unknown
(7), but the hormone is accessible for interaction with
T4!) antibody, which is excluded from the fluid inside
the gel particles. Thyroxine is more firmly bound by
thyroxine binding globulin than by Sephadex.
The new method is compared with the combination of
total thyroxine and T3 uptake expressed as the T4-RT3U
index and with a commercially available normalised
thyroxine assay ("Quantisorb"; Abbott Laboratories,
North Chicago, 111. 60064), a procedure in which
thyroxine is displaced from proteins by acid hydrolysis.
Proteins are not discarded; after adjustment of the pH
by addition of barbital buffer, competition takes place
with a fixed amount of thyroxine binding globulin. Resin
sponges are used to separate the free and protein-bound
moieties.
In a forthcoming paper (8) the estimation of T4N, using
goat thyrqxine antibody, will be reported.
Experimental
Materials and reagents
Sephadex G 25 columns
Disposable Sephadex G25 columns (Cyclotron and Isotope
Laboratories, 1755 ZG Fetten, Holland), 18 mm long and
12 mm inner diameter, with a bed volume of 2 ml were used.
Sephadex was swollen in 0.1 mol/1 NaOH for the estimation of
thyroxine or normalised thyroxine, and in 75 rnmol/1 barbital
buffer, pH 8.6 for the estimation of T3 uptake.
Barbital buffer, 75 mmol/1 pH 8.6
Dissolve 15.45 g of S^'^diethyl^barbituric acid sodium salt in
about 800 ml of distilled water. Adjust the pH to 8.6 with
0.2 mo I/liter hydrochloric acid and dilute to 1000 ml with dis-
tilled water.
125/ labelled triiodothyronine and thyroxine
1125I1T3 and [125I1T4, used in a specific activity of 2.22 MBq/
Mg, were obtained from Philips-Duphar B.V., Cyclotron and Iso-
tope Laboratories, 1755 ZG Fetten, Holland.
Standard thyroxine solution
A serum standard was prepared by adding a known amount of
pure Na-T4 · 5Η^Ο (Henning, Berlin) to calf serum* taking into
account its residual concentration.
Thyroxine binding globulin solution
Membrane-filtered calf serum was diluted 1 : 10 in water with
15.4 mmol/1 Na^azide as preservative. If stored at 4°C, this
thyroxine binding solution remains stable for more than a year.
Assays
l ) T3 = triiodothyronine, T4 = thyroxine
Total thyroxine concentrations in sera (T4D) were measured in
Sephadex columns according to the method of Braverman et al
(5).
RT3U (T3 uptake) .
The RT3U ratio (4) in human sera was measured using small
Sephadex columns swollen in barbital buffer as follows:
Oi5 ml 1 125I]T3 (3.7 kBq) was pipetted onto a Sephadex column,
then 50 μΐ of patient's serum was added. After mixing and
draining, the column was eluted with 2 ml distilled water. The
activity of a column in which standard serum (pooled human
serum of at least 300 individuals) was treated in the same way.
The RT3U ratio was calculated in the following way:
RT3U ratio = |
b
in which Ρ ?= number of counts of the patient's serum
S = number of counts of the standard serum
T4-RT^U index
The T4-RT3U index was defined as: T4(D) χ RT3 ratio (4).
T^N test procedure
The test conditions were chosen so that the contribution of the
second serum sample to the total binding capacity of the eluting
mixture containing thyroxine binding globulin,* was approxi-
mately one third (1).
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The determination of the normalised thyroxine (T4N) or
effective thyroxine ratio (ETR) (6) by the Sephadex column
method was carried out at room temperature as follows:
0.5 ml containing 3.7 kBq [ 12SI]T4 was pipetted onto a column
containing Sephadex G25 swollen in 0.1 mol/1 NaOH. After
pipetting a 0.1 ml serum sample the thyroxine was liberated
from the serum proteins by NaOH. After buffering the Sephadex
column by treating it with 4 ml 75 mmol/1 barbital pH 8.6 and
adding 0.5 ml eluting solution containing thyroxine binding
globulin, the second serum sample (25 μΐ) was applied.
After two minutes incubation on the column, elution of the
Sephadex with 4 ml barbital buffer effects a separation of free-
and bound thyroxine. This step was followed by measurement
of the radioactivity of the columns (free thyroxine).
The count rate of each test serum was compared with a cali-
bration graph produced from duplicate tests using 100 μΐ of
standard serum, containing 129 nmol/1 thyroxine. No second
serum additions were made. This standard point was defined as
corresponding to 20 normalised thyroxine units and extra-
polated to the origin by a straight line. The serum test results
were read from the derived calibration line.
The definition of normalised units was chosen so that the T4N
value of a human pool serum corresponded to the T4 content
expressed in Mg/dl and to the T4-RT3U index (4).
Comparison ofT^N with T^N Quantisorb
The Quantisorb kit of Abbott, which employs a
numeration for T4N units corresponding to the methods
described above, was used as a reference method for
the T4N determination.
44 other freshly drawn serum samples from patients
with suspected thyroid disorders were measured for
T4N by the Sephadex column method and by T4N
determination with the Quantisorb kit. All determinations
were in duplicate. With each method, all tests were
carried out in one day. Figure 2 shows the correlation
between the two methods, the correlation coefficient was
0.93.
Results
Comparison ofTfl with the T4-RT3U ratio
44 freshly drawn serum samples from patients with
suspected thyroid disorders were subjected to determ-
ination of the RTaU ratio, T4(D) and T4N in Sephadex
columns. All determinations were in duplicate. With
each method, all tests were carried out in one day. T4N
values were plotted against T4-RT3U ratio values.
Figure 1 shows the correlation between the two methods.
The correlation was evident, the coefficient of correlation
being 0.83.
This correlation proved to be better than in the com-
parison of T4N with T4D or with the RT3U ratio
alone, indicating that the T4N determination is a comprise
for both the T3 binding properties in the sera under
study.
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Fig. 2. Comparison between T4N by Sephadex column and T4NQuantisorb in 44 human sera; r = 0.93; y = 0.93x - 0.9;
x = 0.93y+2.2.
Reproducibility
The intra-assay variation was between C V = 5 % and
CV =
The interassay (day-to-day) variation was determined by
running seven reference sera of low, medium and high
T4N levels together with other patients' sera on seven
separate days. Table 1 shows the T4N values of the
Tab. 1. T4N day-to-day variation of reference sera tested on
seven separate days.
Fig. 1. Comparison between T4N by Sephadex column and
T4-RT3U index in 44 human sera; r = 0.83; y = 1.02x
+ 0.9;x=1.42y-4.8.
Reference
serum
1
2
3
4
5
6
7
Mean T4N
[Units]
5.4
9.0
17.1
8.9
9.4
10.9
24.5
S.D.
0.4
0.4
1.0
0.6
0.7
0.9
1.1
CV
[%]
7.4
4.4
5.8
6.7
7.4
8.3
4.5
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reference sera and the respective standard deviations
and CV values for the day-to-day variation for single
determinations.
The mean interassay variation of all seven sera was
approximately CV = 6%.
Discussion
The method described gives the same parameter as the
product of T3 uptake and T4, which is an estimate of
free thyroxine. However, the product is an indirectly
obtained figure that is subject to errors from both
assays. Therefore a single test for evaluating thyroid
metabolic status, making use of an appropriate Sephadex
column system, offers a better opportunity for a reliable
and reproducible assay of thyroid function.
The satisfactory correlation with the T4-RT3U index
and the favourable figures for mtra-assay variation (CV
between 5% and 6%) and interassay variation (CV = 6%)
give strong experimental support to this assumption.
The Sephadex column system has already proved its
reliability in thyroxine testing (7, 9, 10). The strong
advantages are the easy handling procedure and the
absence of centrifugation; the limiting time factor is
the elution velocity of the buffers through the Sephadex
columns. Excluding counting time, it takes only 30—45
minutes to process 10 samples.
The second advantage of the Sephadex column system
above other commercially available T4N methods is the
relative insensitivity to interfering lipids which are
present in different quantities in patients' sera. It is
known that nonesterified fatty acids inhibit the binding
of radioactive thyroxine by thyroxine binding globulin.
This inhibition leads to falsely elevated estimates of
serum T4 by competitive protein binding analysis. Such
methods for thyroxine which utilize direct analysis of
alcoholic extracts of serum without prior solvent
evaporation are especially susceptibel to interference by
non-esterified fatty acids (11, 12).
In the method under study the liberation of thyroxine
from its serum proteins is complete, due to the alkaline
denaturation step at the beginning of the test. The
columns are washed consecutively with buffer to shift
the pH of the columns to 8.6 and to wash out any free
125I and serum proteins, including interfering substances
such as lipids, before the real competitive binding stage
starts. The test is therefore rather insensitive to the
presence of free lisl in the T4 tracer and to the presence
of lipids and other interfering substances, such as
salicylates in the sample (13).
A disadvantage of the system under study could be the
relative high price of Sephadex columns, but the
Sephadex columns can be easily regenerated by removing
residual T4 tracer by serum elution, so that the Sephadex
columns are reusable (10).
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